Warncke Katharina, Kummer Sebastian, Kann Peter Herbert, Bergis Dominik, Bollow Esther, Hummel Michael, Zoicas Flavius, Wernert Sebastian, Holl Reinhard W
Department of Pediatrics, Klinikum rechts der Isar, Technische Universität München, Munich, Germany.
Department of General Pediatrics, Neonatology and Pediatric Cardiology, University Children's Hospital, Duesseldorf, Germany.
Exp Clin Endocrinol Diabetes. 2020 Feb;128(2):104-110. doi: 10.1055/a-0600-9649. Epub 2018 Oct 17.
Although diabetes is a common complication of acromegaly or Cushing´s disease, there are only few detailed studies with a focus on cardiovascular risk, metabolic control or diabetes therapy. Here, we provide a comprehensive characterization from the longitudinal DPV (Diabetes Patienten Verlaufsdokumentation) registry.
Patients from the registry≥18 years of age with diabetes and acromegaly or Cushing´s disease were compared to patients with type 1 diabetes or type 2 diabetes using the statistical software SAS 9.4.
Patients with diabetes and acromegaly (n=52) or Cushing's disease (n=15) were significantly younger at diabetes onset (median age 50.1 and 45.0 vs. 59.0 years in type 2 diabetes; both p<0.05). Dyslipidemia was common in both diseases (71.0% and 88.9% vs. 71.8% in type 2 diabetes; n.s.), while hypertension was most frequent in acromegaly (56.8% vs. 20.9% in type 1 diabetes, p<0.00001). 36.5% of patients with acromegaly and 46.7% with Cushing´s disease receive insulin, compared to 50.4% with type 2 diabetes. Oral antidiabetic drugs were used in 36.5% of patients with acromegaly and 40% with Cushing´s disease, with a predominance of biguanides and dipeptidyl peptidase-4 inhibitors. HbA1c was well controlled in both groups (median 7.0% and 6.5%; vs. 7.2% in type 2 diabetes).
Patients with acromegaly are at a high risk for cardiovascular disease, reflected by dyslipidemia and hypertension. A high proportion of patients with diabetes in acromegaly or Cushing´s disease receives insulin. Based on a multicenter register, a sufficient number of patients with rare forms of diabetes can be analyzed.
尽管糖尿病是肢端肥大症或库欣病的常见并发症,但仅有少数详细研究关注心血管风险、代谢控制或糖尿病治疗。在此,我们通过纵向糖尿病患者病程记录(DPV)登记系统进行了全面描述。
使用统计软件SAS 9.4,将登记系统中年龄≥18岁的糖尿病合并肢端肥大症或库欣病患者与1型糖尿病或2型糖尿病患者进行比较。
糖尿病合并肢端肥大症患者(n = 52)或库欣病患者(n = 15)糖尿病发病时明显更年轻(中位年龄分别为50.1岁和45.0岁,2型糖尿病为59.0岁;均p < 0.05)。两种疾病中血脂异常均很常见(分别为71.0%和88.9%,2型糖尿病为71.8%;无显著差异),而高血压在肢端肥大症中最为常见(56.8%,1型糖尿病为20.9%,p < 0.00001)。36.5%的肢端肥大症患者和46.7%的库欣病患者使用胰岛素,2型糖尿病患者为50.4%。36.5%的肢端肥大症患者和40%的库欣病患者使用口服降糖药,以双胍类和二肽基肽酶 - 4抑制剂为主。两组糖化血红蛋白(HbA1c)控制良好(中位值分别为7.0%和6.5%;2型糖尿病为7.2%)。
血脂异常和高血压表明肢端肥大症患者心血管疾病风险较高。肢端肥大症或库欣病合并糖尿病的患者中很大一部分使用胰岛素。基于多中心登记系统,可以分析足够数量的罕见糖尿病患者。